Alliance for Regenerative Medicine (ARM) list of approved regenerative medicines

Posted: 13 August 2024

In 2024, we have more diversity in drug modalities than ever before. While small molecule and large molecule medicines represent a vast share of the market, regenerative (or advanced) medicines are growing in relevance. The types of medicines include cell and gene therapies (CGTs), cord blood therapies and tissue-engineered products. CGTs also include both in vivo and ex vivo gene therapies (gene-modified cell therapies) and numerous autologous and allogeneic cell therapies leveraging different types of immune and stem cells.

Progress in the space is happening every day, and a great place to stay up to date is with ARM’s list of approved products by regulatory bodies around the world. The list includes cell-based immunotherapy products, gene therapy products, cell therapy products, cord blood therapies, and tissue-engineered products.

It is noticeable that cancer is the predominant indication targeted by most advanced therapies today, but this is changing. There are treatments that have also been approved for hepatitus, sickle-cell disease, β-thalassaemia, spinal muscular atrophy, Duchenne Muscular Dystrophy, inherited retinal and other rare diseases, and many others in discovery and development. The European Union and United States represent the most mature markets for CGTs. Other countries with multiple approvals include Japan, Canada, the Republic of Korea, and China.